Aclasta Receives European Approval As First Once Yearly Treatment For Postmenopausal Osteoporosis
Aclasta (zoledronic acid 5 mg) has received European Union approval as the first once yearly treatment for women with postmenopausal osteoporosis. The announcement closely follows the recent approval in the US, where the Food and Drug Administration (FDA) approved Aclasta under the brand name Reclast in August 2007. The European Commission decision applies to all 27 member states, Norway and Iceland.
